Abstracts Archive - Page 2218 of 2425 - ACR Meeting Abstracts

Abstract Number: 467 • 2013 ACR/ARHP Annual Meeting
Adherence To Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) In Rheumatoid Arthritis (RA) Patients Treated In Association With a Biologic: A French Cross-Sectional Survey
Jean-Charles Balblanc¹, Philippe Dieude², Emilie Desfleurs³, Jeanne Antheaume³ and Chantal Deslandre⁴, ¹Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ²Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ³Rheumatology, Roche SAS, Boulogne-Billancourt, France, ⁴Rheumatology, Cochin Hospital, Paris, France
Background/Purpose: A recent meta-analysis of aTNF and abatacept clinical trials established in those drugs that the efficacy of combination therapy with biologic is superior to…
Abstract Number: 468 • 2013 ACR/ARHP Annual Meeting
The Differential Role Of T Helper Cells In The Pathogenesis and Responsiveness To Abatacept Therapy In Rheumatoid Arthritis
Shunsuke Fukuyo¹, Shingo Nakayamada², Kunihiro Yamaoka¹, Satoshi Kubo¹, Shigeru Iwata³, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan
Background/Purpose: Abatacept (ABT) works through a different mechanism of action from TNF inhibitors in the treatment of rheumatoid arthritis (RA). ABT decreases T cell responses…
Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Jaime Calvo-Alén¹, Carmela Baamonde², Ignacio Villa¹, Víctor Martínez-Taboada³, Mario Agudo⁴ and Juan Gómez-Gerique⁵, ¹Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ²Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
Abstract Number: 470 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels
Christina Charles-Schoeman¹, Steven P. Weinstein², Janet van Adelsberg³, Tanya Momtahen⁴, Richard Wu⁵, Neil Graham⁶ and Stefano Fiore⁷, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα) which is currently being evaluated for…
Abstract Number: 471 • 2013 ACR/ARHP Annual Meeting
Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission
Joaquín Borrás-Blasco¹, Antonio Gracia-Pérez², Dolores-Elvira Casterá¹, J. Dolores Rosique-Robles¹, Javier Abad¹ and Alejandro González Álvarez³, ¹Pharmacy Service, Hospital de Sagunto, Sagunto, Spain, ²Rheumatology Service, Hospital de Sagunto, Sagunto, Spain, ³Hospital Obispo Polanco, Teruel, Spain
Etanercept 25 mg once weekly program for rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients in sustained clinical and radiological remissionBackground/Purpose: Etanercept 50mg/week (ETN50) has…
Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Julie Azaïs¹, Thomas Barnetche², Pascale Vergne-Salle³, Christine Bonnet⁴, Carine Dufauret-Lombard⁵, Richard Treves⁶ and Philippe Bertin⁷, ¹Rheumatology department, CHU Dupuytren Limoges, Limoges, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, CHU Dupuytren Limoges, limoges, France, ⁴department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁵Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁶Department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁷Service De Rhumatologie, CHU Dupuytren Limoges, Limoges, France
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…
Abstract Number: 473 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience
Denis Choquette¹, William Bensen², Andrew Chow³, John T. Kelsall⁴, Maqbool K. Sheriff⁵, Jude F. Rodrigues⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Francois Nantel⁹, Susan M. Otawa¹⁰ and Allen J. Lehman¹⁰, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Efficacy and safety of anti-TNF in rheumatoid arthritis (RA) management has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
Abstract Number: 474 • 2013 ACR/ARHP Annual Meeting
HM-0523, a Novel Syk Inhibitor Significantly Ameliorates The Severity Of Arthritis In Rodents
Yu Cai¹, Zhong Cui Sun¹, Ping Ren¹, Lei Fang¹, Xiaoming Dai¹, Zhipeng Wu¹, Qianqian Dong², Xinrong Wang¹, Jian Wang¹, Yang Sai¹, Xiong Li¹ and Weiguo Su¹, ¹Hutchison Medipharma Limited, Shanghai, China, ²Inflammation & Immunology Research, Hutchison Medipharma Limited, Shanghai, China
Background/Purpose: Spleen tyrosine kinase (SYK) is a key mediator of signaling events downstream of a wide array of receptors important for immune function, including the…
Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Birgul Ay¹, Dilek Keskin², Goksal Keskin³ and Ayhan Dinc⁴, ¹Internal Medicine, DYB Research and Training Hospital, Ankara, Turkey, ²Immunology, DYB Research and Training Hospital, Ankara, Turkey, ³Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, ⁴Rheumatology, Patio Clinic, Ankara, Turkey
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…
Abstract Number: 476 • 2013 ACR/ARHP Annual Meeting
Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab
Roy Fleischmann¹, M Schiff², M E Weinblatt³, M Maldonado⁴, E Massarotti⁵ and Y Yazici⁶, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³Brigham & Women's Hospital, Boston, MA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Brigham and Women's Hospital, Boston, MA, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Remission and low disease activity (LDA) are now more achievable goals in RA. Year 1 data from the head-to-head AMPLE (Abatacept vs Adalimumab Comparison…
Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
B Dasgupta¹, P Bertin², L Settas³, JE Fonseca⁴, V Wolff⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Dupuytren, Limoges, France, ³AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece, ⁴Lisbon Academic Medical Centre, Lisboa, Portugal, ⁵Hospital del Salvador, Santiago, Chile, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…
Abstract Number: 478 • 2013 ACR/ARHP Annual Meeting
Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients
René Galien¹, Béatrice Vayssière¹, Steve de Vos², Marielle Auberval¹, Nick Vandeghinste², Sonia Dupont¹, Philippe Clément-Lacroix¹, Philippe Delerive¹, Frédéric Vanhoutte², Reginald Brys², Annegret Van der Aa², Luc Van Rompaey² and Gerben van 't Klooster², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that transduce intracellular signaling for cytokines including interleukins and interferons, and…
Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…
Abstract Number: 457 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling
Yauheniya Cherkas, Carrie Brodmerkel, Mark Curran and Sarah Lamberth, Janssen Research & Development, LLC., Spring House, PA

Background/Purpose: RA is a chronic systemic autoimmune disease resulting in joint inflammation and damage. Despite the current therapies available, only a small percentage of RA…
Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
C. Charles-Schoeman¹, P Wicker², M. A. Gonzalez-Gay³, S. P. Wood⁴, M.G. Boy⁴, J. Geier⁵, D. Gruben⁴, K. Soma⁴ and R. Riese⁴, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²PW Consulting LLC, Mystic, CT, ³Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].